Cost-effectiveness of direct-acting antiviral regimen ombitasvir/paritaprevir/ritonavir in treatment-naïve and treatment-experienced patients infected with chronic hepatitis C virus genotype 1b in Japan. [electronic resource]
Producer: 20170629Description: 1144-1156 p. digitalISSN:- 1941-837X
- Anilides -- economics
- Antiviral Agents -- economics
- Carbamates -- economics
- Cost-Benefit Analysis
- Cyclopropanes
- Drug Therapy, Combination
- Female
- Genotype
- Hepacivirus -- drug effects
- Hepatitis C, Chronic -- drug therapy
- Humans
- Japan
- Lactams, Macrocyclic
- Macrocyclic Compounds -- economics
- Male
- Middle Aged
- Models, Economic
- Proline -- analogs & derivatives
- Ritonavir -- economics
- Sulfonamides
- Valine
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.